Generic Cipro Availability

Cipro is a brand name of ciprofloxacin, approved by the FDA in the following formulation(s):

CIPRO (ciprofloxacin - for suspension;oral)

  • Manufacturer: BAYER HLTHCARE
    Approval date: September 26, 1997
    Strength(s): 250MG/5ML [AB], 500MG/5ML [RLD] [AB]

CIPRO (ciprofloxacin - injectable;injection)

  • Manufacturer: BAYER HLTHCARE
    Approval date: December 26, 1990
    Strength(s): 400MG/40ML (10MG/ML) [RLD] [AP], 200MG/20ML (10MG/ML) [RLD] [AP]

CIPRO (ciprofloxacin hydrochloride - tablet;oral)

  • Manufacturer: BAYER HLTHCARE
    Approval date: October 22, 1987
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [RLD] [AB], EQ 750MG BASE [AB]
  • Manufacturer: BAYER HLTHCARE
    Approval date: April 8, 1996
    Strength(s): EQ 100MG BASE [AB]

Has a generic version of Cipro been approved?

A generic version of Cipro has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cipro and have been approved by the FDA:

ciprofloxacin for suspension;oral

  • Manufacturer: LUPIN LTD
    Approval date: March 5, 2014
    Strength(s): 250MG/5ML [AB], 500MG/5ML [AB]

ciprofloxacin injectable;injection

  • Manufacturer: CLARIS LIFESCIENCES
    Approval date: April 29, 2008
    Strength(s): 200MG/20ML (10MG/ML) [AP], 400MG/40ML (10MG/ML) [AP]
  • Manufacturer: HIKMA FARMACEUTICA
    Approval date: December 22, 2009
    Strength(s): 200MG/20ML (10MG/ML) [AP], 400MG/40ML (10MG/ML) [AP]
  • Manufacturer: HOSPIRA
    Approval date: August 28, 2006
    Strength(s): 200MG/20ML (10MG/ML) [AP], 400MG/40ML (10MG/ML) [AP]

ciprofloxacin hydrochloride tablet;oral

  • Manufacturer: APOTEX
    Approval date: November 4, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: AUROBINDO PHARMA
    Approval date: April 26, 2007
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: CARLSBAD
    Approval date: June 9, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: June 9, 2004
    Strength(s): EQ 100MG BASE [AB], EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: HIKMA
    Approval date: June 9, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: IVAX SUB TEVA PHARMS
    Approval date: June 9, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: MYLAN
    Approval date: June 9, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: MYLAN
    Approval date: June 25, 2007
    Strength(s): EQ 100MG BASE [AB]
  • Manufacturer: RANBAXY
    Approval date: June 9, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: TARO
    Approval date: October 6, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: TARO
    Approval date: February 18, 2005
    Strength(s): EQ 100MG BASE [AB]
  • Manufacturer: UNIQUE PHARM LABS
    Approval date: September 10, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: WATSON LABS
    Approval date: June 9, 2004
    Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 750MG BASE [AB]
  • Manufacturer: WATSON LABS
    Approval date: February 10, 2005
    Strength(s): EQ 100MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cipro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Flavor-masked pharmaceutical compositions
    Patent 5,695,784
    Issued: December 9, 1997
    Inventor(s): Pollinger; Norbert & Michaelis; Johannes & Benke; Klaus & Rupp; Roland & Bucheler; Manfred
    Assignee(s): Bayer Aktiengesellschaft
    The invention relates to flavour-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.
    Patent expiration dates:
    • December 9, 2014
    • June 9, 2015
      ✓ 
      Pediatric exclusivity
  • Flavor-masked pharmaceutical compositions
    Patent 6,136,347
    Issued: October 24, 2000
    Inventor(s): Pollinger; Norbert & Michaelis; Johannes & Benke; Klaus & Rupp; Roland & Bucheler; Manfred
    Assignee(s): Bayer Aktiengesellschaft
    The invention relates to flavor-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.
    Patent expiration dates:
    • July 6, 2013
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Hide
(web5)